Prevalence of anemia and chronic kidney disease in cancer patients: Clinical significance for 1-year mortality

Japanese Journal of Nephrology

Volumn 53, Issue 1, 2011, Pages 38-45

  Nakamura, Yuya ^a   Tsuchiya, Ken ^b   Nitta, Kosaku ^b   Ando, Minoru ^a,b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anemia; Anemia severity grade; Cancer patients; Chronic kidney disease

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC KIDNEY DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; RATING SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CHRONIC DISEASE; COMORBIDITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 79952298651     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005 ; 352 : 1011-1023.
2. Grotto HZ. Anaemia of cancer : an overview of mechanisms involved in its pathogenesis. Med Oncol 2008 ; 25 : 12-21.
3. Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S. Cancer-related anemia : pathogenesis, prevalence and treatment. Oncology 2005 ; 68 : 3-11.
4. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998 ; 25 : 2-6. (Pubitemid 28326216)
5. Jacobi N, Rogers TB, Peterson BA. Prognostic factor in follicular lymphoma : single institution study. Oncol Rep 2008 ; 20 : 185-193.
6. Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transi Oncol 2006 ; 8 : 22-30.
7. Park SH, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2006 ; 57 : 91-96.
8. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood 2004 ; 104 : 1258-1265.
9. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer : a systematic review of the literature. Am J Med 2004; 116 : 11S-26S.
10. Bokemeyer C, Oechsle K, Hartmann JT, Schöffski P, Schleucher N, Metzner B, Schleicher J, Kanz L. Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 2002 ; 87 : 1066-1071. (Pubitemid 35418099)
11. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer : a systemic, quantitative review. Cancer 2001 ; 91 : 2214-2221. (Pubitemid 32552805)
12. Coiffier B. The impact and management of anaemia in haematological malignancies. Med Oncol 2000 ; 17 : 52-10.
13. Leonard RC, Hayward RL, Prescott RJ, Wang JX. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1991 ; 2 : 655-662.
14. Denison U, Baumann J, Peters-Engl C, Samonigg H, Krippl P, Lang A, Obermair A, Wagner H, Sevelda P. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2003 ; 79 : 347-353. (Pubitemid 36750942)
15. Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, Craig JC. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009 ; 20 : 1341-1350.
16. Cucković C, Djukanović L, Janković, Stanojcić A, Dragićević P, Radmilović A, Lambić L, Stojánović M, Milić M, Baković J, Radović M, Labudović M. Malignant tumors in hemodialysis patients. Nephron 1996 ; 73 : 710-712. (Pubitemid 26258215)
17. Lindner A, Farewell VT, Sherrard DJ. High incidence of neoplasia in uremic patients receiving long-term dialysis. Cancer and long-term dialysis. Nephron 1981 ; 27 : 292-296. (Pubitemid 11072574)
18. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet 1975 ; 19 : 883-886.
19. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351 : 1296-1305.
20. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009 ; 53 : 982-992.
21. National-Kidney-Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease : evaluation, classification and stratification. Am J Kidney Dis 2002 ; 39 : S1-S266.
22. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D. The European Cancer Anaemia Survey (EGAS) : a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004 ; 40 : 2293-2306.
23. Seshadri T, Prince HM, Bell DR, Coughlin PB, James PP, Richardson GE, Chern B, Briggs P, Norman J, Olver IN, Karapetis C, Stewart J ; Australian Cancer Anaemia Study Group. The Australian Cancer Anaemia Survey : a snapshot of anaemia in adult patients with cancer. Med J Aust 2005 ; 182 : 453-457.
24. Kitano T, Tada H, Nishimura T, Teramukai S, Kanai M, Nishimura T, Misawa A, Yoshikawa K, Yasuda H, Ishiguro H, Matsumoto S, Yanagihara K, Fukushima M. Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy. Int J Hematol 2007 ; 86 : 37-41. (Pubitemid 47204488)
25. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma : findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol 2006 ; 77 : 378-386. (Pubitemid 44483940)
26. Cazzola M. Mechanisms of anaemia in patients with malignancy : implications for the clinical use of recombinant human erythropoietin. Med Oncol 2000 ; 17 : S11-16.
27. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009 ; 13 : 621-630.
28. Iseki K, Ikemiya Y, Iseki C, Takishita S. Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 2003 ; 18 : 899-905. (Pubitemid 36592530)
29. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004 ; 66 : 1131-1138.
30. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer : 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008 ; 111 : 25-41.